FGF23 neutralization improves bone quality and osseointegration of titanium implants in chronic kidney disease mice

Citation
Sun, Ningyuan, Yuchen Guo, Weiqing Liu, Michael Densmore, Victoria Shalhoub, Reinhold G. Erben, Ling Ye, Beate Lanske, and Quan Yuan. 2015. “FGF23 neutralization improves bone quality and osseointegration of titanium implants in chronic kidney disease mice.” Scientific Reports 5 (1): 8304. doi:10.1038/srep08304. http://dx.doi.org/10.1038/srep08304.

Published Version
doi:10.1038/srep08304

Permanent link
http://nrs.harvard.edu/urn-3:HUL.InstRepos:14065514

Terms of Use
This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA

Share Your Story
The Harvard community has made this article openly available. Please share how this access benefits you. Submit a story.

Accessibility
FGF23 neutralization improves bone quality and osseointegration of titanium implants in chronic kidney disease mice

Ningyuan Sun1, Yuchen Guo1, Weiqing Liu1, Michael Densmore2, Victoria Shalhoub3*, Reinhold G. Erben4, Ling Ye1, Beate Lanske2 & Quan Yuan1,2

1State Key Laboratory of Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu, China, 2Department of Oral Medicine, Infection, and Immunity, Harvard School of Dental Medicine, Boston, MA, 3Amgen Inc., Thousand Oaks, CA, USA, 4Department of Biomedical Sciences, University of Veterinary Medicine, Vienna, Austria.

Chronic kidney disease (CKD) is a worldwide health problem. Serum levels of FGF23, a phosphaturic hormone, increase at the earliest stages of CKD, and have been found to be independently associated with the mortality and morbidity of CKD patients. The purpose of this study was to evaluate whether FGF23 neutralization was able to improve bone quality and osseointegration of titanium implants. Uremia was induced by 5/6 nephrectomy in adult female mice. Postsurgery, the mice were injected with vehicle or FGF23 neutralizing antibody (5 mg/kg body weight) 3 times a week. Experimental titanium implants were inserted in the distal end of the femurs. FGF23 neutralization significantly increased serum phosphate, 1,25(OH)2D and BUN, and decreased serum PTH and FGF23, relative to vehicle-treated CKD mice. Histomorphometric analysis of the tibiae indicated that FGF23 neutralization normalized the osteoidosis observed in vehicle-treated CKD mice. Although bone-implant contact ratio remained unchanged by anti-FGF23 antibody treatment, the strength of osseointegration, as evidenced by a biomechanical push-in test, was significantly improved by FGF23 neutralization. Our findings revealed that FGF23 neutralization effectively improves bone quality and osseointegration of titanium implants in CKD mice, suggesting FGF23 as a key factor of CKD related bone diseases.
FGF23 is independently associated with chronic kidney disease-mineral and bone disorder (CKD-MBD) in CKD patients. A recent study has shown that FGF23 neutralization is, to some extent, able to ameliorate the levels of parathyroid hormone, vitamin D, serum calcium, and to normalize bone markers in uremic rats. We hypothesized that the elevated FGF23 levels in CKD patients impair bone structure and quality, which in turn can be an obstacle to the osseointegration of titanium dental implants. To test this hypothesis, we used FGF23 antibody to neutralize the function of FGF23, and investigated trabecular bone turnover and osseointegration of a titanium implant in a CKD mouse model.

Methods

Ethics Statement. This study was performed in strict accordance with the recommendations contained in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health and the ARRIVE guidelines (http://www.ncrs.org.uk/arrive-guidelines). All of the experiments carried out were approved by the Subcommittee on Research and Animal Care (SRAC), which serves as the Institutional Animal Care and Use Committee at the Harvard Medical School (protocol number: 03901). All surgery was performed under anesthesia by intraperitoneal injection of a combination of ketamine (100 mg/ml) and xylazine (10 mg/ml), in addition, buprenorphine (0.05 mg/kg) was given for perioperative analgesia to minimize suffering and pain.

Animals. Nine-week-old female C57BL mice were purchased from Charles River Laboratories International Inc. (Wilmington, MA). The animals were kept under climate-controlled conditions and fed with standard diet. All studies were approved by the Institutional Animal Care and Use Committee at the Harvard Medical School (Boston, MA). The mice were randomly divided into 4 groups, and each group contained 8 animals.

Surgical procedure to induce uremia. The CKD mice were established by a two-step 5/6 nephrectomy to induce uremia as described previously. Briefly, the left kidney was approached through a 2-cm-long lumbar incision and exposed by fine dissection of the peri-renal fat and adrenal gland. The left kidney was lacerated except for a 2-mm area around the hilum. The kidney was then returned to the renal fossa, and the subcutaneous tissues were sutured with 6-0 silk. The skin was closed with surgical clips. After 1 week, a total nephrectomy of the right kidney was performed by ligation of the renal hilum with a 5-0 silk suture and surgical excision of the kidney. The wound was closed as the first surgery. Sham surgery consisted of anesthetic, flank incision exposing the kidney, and closure of the abdominal wall.

Administration of neutralizing FGF23 antibody. Neutralizing FGF23 Ab was kindly provided by Amgen Inc. (Thousand Oaks, CA). It was diluted in PBS and administered intraperitoneally 3 times per week (5 mg/kg body weight). The administration was started 8 weeks after the second renal surgery and continued for a period of 4 weeks. An illustration of the workflow is shown in Figure 1. Day 0 of the study is defined as the date of the second renal ablation.

Implant surgery. Ten weeks after the second renal ablation surgery, the mice were subjected to implant placement by the method described previously. Titanium implants with SLA surface (1 mm in diameter and 4 mm in length) were kindly provided by Institut Straumann AG (Basel, Switzerland). They were cut to the length of 2 mm before insertion. The distal aspect of the femurs was carefully exposed after the skin incision and fine muscle dissection. The implant site was prepared on the medial surfaces of each femur by sequential drilling with 0.7- and 1.0-mm surgical stainless steel twist drills. The implant was press-fitted into the hole for primary stability. After the insertion of the implant, the muscles were carefully sutured with 6-0 silk, which covered the implant and further guaranteed its protection in the biological environment. Then the skin was closed with 5-0 silk. Eight mice were allocated to each group.

Serum biochemical assays. Twelve weeks after the second renal surgery, blood was collected by cheek pouch before sacrifice of the mice. Serum biochemistry was performed using commercially available kits: Blood urea nitrogen (BUN) (Stanbio Laboratory, Boerne, TX); FGF23 (Immunopectics, San Clemente, CA, Cat. #60-6300), PTH (Immunopectics, San Clemente, CA); 1,25(OH)2D (Immunodiagnostic Systems Ltd., Fountain Hills, AZ); Calcium and Phosphate (Stanbio Laboratory, Boerne, TX).

Histological preparation and histomorphometric measurement. The processing of uncalcified bone specimens and cancellous bone were performed as described previously. Femurs and tibiae were fixed in 10% buffered formalin at 4°C overnight and stored in 70% ethanol at 4°C. Specimens were exposed to X-ray (20 kV, 5 seconds) before being processed. The total mineral content (TOT_CNT) and mineral density (TOT_DEN) of proximal tibiae were assessed by peripheral quantitative computerized tomography (pQCT), as described previously. The tibiae were embedded in methylmethacrylate and three-μm-thick mid sagittal sections were prepared using a HM 360 microtome (Microm, Walldorf, Germany). Histomorphometric measurements in the proximal ends were made on sections stained with von Kossa/McNeal using a semiautomatic system (OsteoMeasure, OsteoMetrics, Decatur, GA), and a Zeiss Axioskop microscope with a drawing attachment. The area within 0.25 mm of the growth plate was excluded from the measurements. All histomorphometric parameters were calculated and expressed according to the suggestions made by the ASBMR nomenclature committee.

Implant biomechanical push-in test. The right side of the femur containing a cylindrical implant from each mouse was dehydrated and embedded into auto-polymerizing resin with the top surface at the implant level. A testing machine (AG-TA electronic universal testing machine, SHIMADZU, Japan) equipped with a pushing rod (diameter = 0.8 mm) was used to load the implant vertically downward at a crosshead speed of 1 mm/min. The push-in value was determined by measuring the peak of the load-displacement curve.

Statistical analysis. All values are presented as mean ± SD. Statistically significant differences were assessed by ANOVA followed by Turkey’s multiple comparisons, or by independent student t test for comparisons between two groups. A p value of less than 0.05 was considered to be statistically significant.

Results

Serum biochemistry. Significant differences were observed between the sham + vehicle group and the CKD + vehicle group in terms of serum BUN (Fig. 2A), FGF23 (Fig. 2D), PTH (Fig. 2E), and Vit D (Fig. 2F), indicating successful establishment of the uremic mouse model. Injection of FGF23 Ab did not change the BUN levels in the normal mice, but further elevated the levels in CKD mice from 43.87 ± 5.33 mg/dl to 65.62 ± 11.17 mg/dl (p < 0.05). The serum calcium levels remained stable (Fig. 2B), while the phosphate levels were significantly increased in both sham and CKD mice after FGF23 Ab injection (Fig. 2C). The serum FGF23 level in the CKD mice was over 2-fold higher than that of control, and it was restored to the normal level after FGF23 Ab administration (Fig. 2D). Similarly, the hyperparathyroidism observed in the CKD mice was significantly decreased after FGF23 Ab treatment (Fig. 2E). As shown in Fig. 2F, serum 1,25(OH)2D in CKD mice was significantly lower than that of sham group. FGF23 Ab injection significantly elevated serum 1,25(OH)2D both in the sham and CKD mice.

FGF23 neutralizing improved bone quality. We then analyzed the response to FGF23 treatment in bone by comparing the proximal tibiae using ex vivo pQCT. No significant difference was observed in

Figure 1 | Illustration of the workflow.
terms of total mineral content (TOT_CNT) and total mineral density (TOT_DEN) between the sham and CKD mice (Fig. 3A&B). FGF23 Ab injection seemed to induce a slight increase of TOT-DEN (Fig. 3B), however there were no significant differences among the four groups in both TOT-CNT and TOT-DEN.

Fig. 4A shows the histological images of undecalcified sections stained with von Kossa and McNeal blue. Increased trabecular bone volume (BV/TV) was observed in CKD mice, but it was restored to a level comparable to that of normal mice after FGF23 Ab administration (Fig. 4B). FGF23 Ab injection also
improved the osteoid volume (OV/TV) and trabecular thickness (Tb.Th). There are no significant differences in the trabecular separation (Tb.Sp), trabecular number (Tb.N) and number of osteoclasts per bone perimeter (N.Oc/B.Pm) among all four groups (Fig. 4E–G). Moreover, we observed that FGF23 neutralization corrected the increased mineral apposition rate (MAR) in
CKD mice (Fig. 4H), while no significant difference was found for bone formation rate (BFR) (Fig. 4I).

FGF23 neutralizing increased fixation of titanium implants. As anticipated, all mice survived the observation period and no inflammation at the implant site was observed. The ex vivo X-ray examination of the femurs showed that the implants were surrounded with bone without any notable gap, indicating successful osteointegration for both groups (Fig. 5A).

The observation of histological sections confirmed a direct bone-implant contact for all four groups (Fig. 5B). Further histomorphometrical analyses did not reveal any statistically significant differences for peri-implant BIC ratio (Fig. 5C). Consistent with our previous report, CKD mouse showed significantly impaired push-in resistance of the titanium implants ($p<0.05$) (Fig. 5D). However, it was significantly increased after FGF23 Ab treatment ($14.45 \pm 3.61$ N) ($p<0.05$), compared to that of vehicle ($10.26 \pm 1.89$ N), indicating an improvement of bone-implant integration (Fig. 5D).
Discussion

In the study, we established a CKD mouse model that was subsequently treated with FGF23 antibody to investigate the effect of FGF23 neutralization on serum changes, bone structure and implant fixation. The treatment successfully neutralized the elevated FGF23 levels, corrected the secondary hyperparathyroidism, and elevated 1,25(OH)2D levels as well. More importantly, the neutralization of FGF23 clearly normalized the bone structure of CKD mice, including the BV/TV, OV/TV, Tb.Th and MAR. FGF23 Ab administration also improved the push-in resistance of the implants. These results indicate that FGF23 plays a key role in CKD related bone diseases.

Vit D is a fundamental micronutrient with major implications for human health. Vit D deficiency, which is defined as a 25(OH)D level of less than 20 ng/ml (50 nmol per liter), is highly prevalent in patients with CKD. Aberrant Vit D metabolism in CKD including decreased synthesis in the skin and urinary loss of Vit D metabolites contribute to this high prevalence. Since the reduction in renal function also diminishes the activity of 1α-hydroxylase (1α-OHase), the enzyme that converts 25(OH)D to its activated form, 1, 25(OH)2D. Serum level of 1,25(OH)2D of CKD + vehicle group decreased significantly compared with sham + vehicle group, however, this parameter increased significantly after FGF23 Ab administration. A major biological function of 1,25(OH)2D is to maintain proper serum phosphorus and calcium concentrations in order to support cellular functions and to promote mineralization of the skeleton. Vitamin D deficiency causes secondary hyperparathyroidism, mineralization defects, bone loss and fractures. In combination with a sufficient calcium supply, vitamin D and its metabolites are able to enhance the calcium balance and facilitate mineral deposition in bone matrix. Our recent study also demonstrated that administration of 1,25(OH)2D3 to CKD mice improves the fixation of titanium implants.

FGF23 Ab administration corrected the hyperparathyroidism of CKD mice in this study. PTH, another key factor of mineral homeostasis, is secreted by the chief cells of the parathyroid glands as a polypeptide and regulates the serum calcium and phosphate levels. Continuous stimulation with PTH accelerates calcium release from bone, and leads to high bone turnover, which subsequently causes abnormal high BV/TV and high osteoid volume. A previous study revealed that continuous infusion of bovine PTH (1–84) resulted in an increase in both osteoblast and osteoclast function, causing increased bone formation and resorption, and a net decrease in trabecular bone volume. Selby et al. studied the forearms of CKD patients and found that there was a negative relationship between bone density and PTH concentration and the bone loss in these patients is related to the secondary hyperparathyroidism. Moreover, this excess PTH directly stimulates FGF23 transcription and secretion. In this study, we showed that FGF23 Ab administration corrected the hyperparathyroidism of CKD mice. The resulting down-regulation of PTH may contribute to the improvement of bone structures and push-in resistance of implants.

In this study, FGF23 levels were normalized upon FGF23 Ab administration. FGF23 plays a major role in balancing mineral ion homeostasis and altered activity can lead to severe disturbances in phosphate metabolism, resulting in either hyperphosphatemia or rickets. Genetic deletion of FGF23 in mice causes severe skeletal defects. In addition, FGF23 itself plays a direct role in inhibiting mineralization. Both adenoviral overexpression of FGF23 in rat calvaria cells or treatment with exogenous FGF23 peptide inhibit differentiation and mineralization of osteoblasts. It is notable that phosphate levels in experimental mice were increased after treatment with FGF23 Ab. This effect is probably due, at least in part, to the inhibition of the phosphaturic activity of FGF23 on the renal kidney. Hyperphosphatemia is a major risk for ectopic calcification. Shalhoub et al. indicated that FGF23 Ab aggravates serum phosphate and artery calcification in CKD rats.
19. Mirza, M. A., Larsson, A., Lind, L. & Larsson, T. E. Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the community. *Atherosclerosis* **205**, 385–390, doi:10.1016/j.atherosclerosis.2009.01.001 (2009).

20. Abraham, B. P., Prasad, P. & Malaty, H. M. Vitamin D deficiency and corticosteroid use are risk factors for low bone mineral density in inflammatory bowel disease patients. *Disease and Science* **59**, 1878–1884, doi:10.1007/s10620-014-3102-x (2014).

21. Gutierrez, O. et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. *Journal of the American Society of Nephrology* : *JASN* **16**, 2205–2215, doi:10.1681/ASN.20051001052 (2005).

22. Portillo, M. R., Lopez, I., Juan, M., Tejero, E. A. & Almaden, Y. FGF23 and mineral metabolism, implications in CKD-MBD. *Nefrologia: publicación oficial de la Sociedad Española de Nefrología* **32**, 275–278 (2012).

23. Seiler, S., Heine, G. H. & Fliser, D. Clinical relevance of FGF-23 in chronic kidney disease. *Kidney International* **76**, S34–S42 (2009).

24. Shalhoub, V. et al. Vitamin D deficiency and secondary hyperparathyroidism in elderly people. *Biochimica et Biophysica Acta* : *Reviews on Biomembranes* **1808**, 1313–1319 (2011).

25. Yuan, Q. et al. Increased osteopontin contributes to inhibition of bone mineralization in FGF23-deficient mice. *Journal of bone and mineral research: the official journal of the American Society for Bone and Mineral Research* **29**, 693–704, doi:10.1002/jbmr.2079 (2014).

26. Erben, R. G. et al. Overexpression of Human PHEX Under the Human β-Actin Promoter Does Not Fully Rescue the Hyp Mouse Phenotype. *Journal of Bone and Mineral Research* **20**, 1149–1160 (2005).

27. Dempster, D. W. et al. Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. *Journal of Bone and Mineral Research* **28**, 2–17 (2013).

28. Holick, M. F. Vitamin D deficiency. *The New England journal of medicine* **357**, 266–281, doi:10.1056/NEJMra070553 (2007).

29. Pilla, S., Iodice, S., Zittermann, A., Grant, W. B. & Gandini, S. Vitamin D status and mortality risk in CKD: a meta-analysis of prospective studies. *American Journal of Kidney Diseases* **58**, 374–382 (2011).

30. Jacob, A. I., Sallman, A., Santiz, Z. & Hollis, B. W. Defective photoproduction of cholecalciferol in normal and uremic humans. *The Journal of Nutrition* **114**, 1313–1319 (1984).

31. Doorenbos, C. R., van den Born, J., Navis, G. & de Borst, M. H. Possible renoprotection by vitamin D in chronic renal disease: beyond mineral metabolism. *Nature reviews. Nephrology* **5**, 691–700, doi:10.1038/nrneph.2009.185 (2009).

32. Holick, M. F. Vitamin D and bone health. *The Journal of Nutrition* **126**, 1159S–1164S (1996).

33. Lips, P. Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. *Endocrine reviews* **22**, 477–501 (2001).

34. Eisman, J. A. & Bouillon, R. Vitamin D: direct effects of vitamin D metabolites on bone: lessons from genetically modified mice. *BoneKey reports* **3**, 499, doi:10.1038/bonekey.2013.233 (2014).

35. Liu, W. et al. Vitamin D supplementation enhances the fixation of titanium implants in chronic kidney disease mice. *PloS one* **9**, e95689, doi:10.1371/journal.pone.0095689 (2014).

36. Raizy, L. G. Bone resorption in tissue culture. Factors influencing the response to parathyroid hormone. *Journal of Clinical Investigation* **44**, 103 (1965).

37. Tamagaki, K. et al. Severe hyperparathyroidism with bone abnormalities and metastatic calcification in rats with adenine-induced uremia. *Nephrology Dialysis Transplantation* **21**, 651–659 (2006).

38. Sun, N. et al. Vitamin D modulation of DMP-1 expression in human keratinocytes. *Science* **331**, 149–153 (2011).

39. Selby, P. L., Davies, M., Adams, J. E. & Mawer, E. B. Bone loss in celiac disease is related to secondary hyperparathyroidism. *Journal of Bone and Mineral Research* **14**, 652–657 (1999).

40. Silver, J. & Naveh-Many, T. FGF-23 and secondary hyperparathyroidism in chronic kidney disease. *Nature reviews. Nephrology* **9**, 641–649, doi:10.1038/nrneph.2013.147 (2013).

41. Bergwitz, C. & Jüppner, H. Regulation of phosphate homeostasis by PTH, vitamin D, and FGF23. *Annual review of medicine* **61**, 91–104 (2010).

42. Sato, S. et al. Dietary fat modification in end-stage renal disease: impact on all-cause and cardiovascular mortality. *Nephrology Dialysis Transplantation* **18**, 1731–1740 (2003).

43. Carpenter, T. O., Santos-Oliva, E. & Tosteson, T. N. Dietary fat modification in end-stage renal disease and cardiovascular disease? *Journal of American College of Cardiology* **39**, 695–701 (2002).

44. Bergwitz, C. & Jüppner, H. Regulation of phosphate homeostasis by PTH, vitamin D, and FGF23. *Annual review of medicine* **61**, 91–104 (2010).

45. Nitta, K. et al. Left ventricular hypertrophy is associated with arterial stiffness and vascular calcification in hemodialysis patients. *Hypertension research: official journal of the Japanese Society of Hypertension* **27**, 47–52 (2004).

46. Raggi, P. et al. Cardiac calcification in adult hemodialysis patients: a link between end-stage renal disease and cardiovascular disease? *Journal of the American College of Cardiology* **39**, 695–701 (2002).

47. Carpenter, T. O. et al. Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia. *The Journal of Clinical Investigation* **124**, 1587 (2014).

48. Huang, X., Lindholm, B., Stenvinkel, P. & Carrero, J. J. Dietary fat modification in patients with chronic kidney disease: n-3 fatty acids and beyond. *Journal of Bone and Mineral Research* **26**, 960 (2013).

Acknowledgments

We thank Agenin Co. for providing the FGF23 neutralizing antibody. This work was supported by grants from the National Natural Science Foundation of China (NSFC 81371173, 81321002), Sichuan Province Youth Fund (2013JQ0017), and 111 project of Ministry of Education of China, and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK, R01-097105) to BL.

Author contributions

Q.Y. and B.L. designed the project. Q.Y., B.L., V.S., R.G.E. and L.Y. designed experiments. Q.Y., N.S., Y.G., W.L. and M.D. performed a significant amount of the experimental work. Q.Y. and B.L. performed most of the data collection and data analysis. Q.Y. and B.L. prepared tables and figures. All authors reviewed the manuscript.

Additional information

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Sun, N. et al. FGF23 neutralization improves bone quality and osseointegration of titanium implants in chronic kidney disease mice. *Sci. Rep.* **5**, 8304; DOI:10.1038/srep08304 (2015).

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder in order to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/